Powered by
Tyme Technologies Appoints Healthcare Veteran Paul L. Sturman as Independent Director
Mar 2, 2017 - GlobeNewswire
Board and Executive Moves

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (OTCQB:TYMI), a specialty biotechnology company developing cancer therapeutics targeted at multiple tumor types, today announced the addition of Paul L. Sturman, a seasoned pharmaceutical executive with 30 years in the consumer health industry at Pfizer, Johnson & Johnson and Warner Lambert, to the company's board of directors.

"As Tyme transforms from being an early-stage biotech company to a more fully integrated one,

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox